15 completed, 5 terminated, 1 unknown. 21 Phase 2, 5 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 15, Terminated 5, Unknown 1 |
| Phase 3 | 5 | Completed 2, Terminated 2, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Uterine Fibroids: new trials by email Literature Review of Uterine Fibroids trials Research Report on Uterine Fibroids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment Microwave treatment, uterine artery embolization - Uterine Fibroids | Phase 2 / Phase 3 | Unknown | Karolinska Institutet | 36 | 2017-01-23 | 2018-10-02 |
| An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids Telapristone acetate - Uterine Fibroids | Phase 2 | Terminated | Repros Therapeutics Inc. | 20 | 2016-07-26 | 2019-06-27 |
| A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids Telapristone Acetate, Placebo - Uterine Fibroids | Phase 2 | Completed | Repros Therapeutics Inc. | 43 | 2015-03-16 | 2019-06-19 |
| Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids Placebo, Telapristone Acetate - Uterine Fibroids | Phase 2 | Completed | Repros Therapeutics Inc. | 42 | 2015-02-12 | 2019-06-25 |
| Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) Elagolix placebo, Elagolix, 0.5 mg estradiol / 0.1 mg norethindrone acetate - Heavy Uterine Bleeding, Uterine Fibroids | Phase 2 | Completed | AbbVie | 571 | 2013-04-08 | 2020-07-21 |
| Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 Proellex 12 mg, Proellex 24 mg - Uterine Fibroids | Phase 2 | Completed | Repros Therapeutics Inc. | 40 | 2012-09-01 | 2014-04-16 |
| Extension of Study ZPV-200 telepristone acetate 12 mg, telepristone acetate 3 mg, telepristone acetate 6 mg - Uterine Fibroids | Phase 2 | Completed | Repros Therapeutics Inc. | 48 | 2012-09-01 | 2014-04-16 |
| Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids MR-HIFU treatment, Sham treatment - Uterine Fibroids | Phase 2 / Phase 3 | Terminated | Philips Healthcare | 49 | 2012-05-01 | 2017-04-05 |
| Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids Proellex - Uterine Fibroids | Phase 2 | Completed | Repros Therapeutics Inc. | 40 | 2012-02-01 | 2014-08-29 |
| Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids TAK-385, Placebo - Uterine Fibroids | Phase 2 | Completed | Takeda | 216 | 2011-10-01 | 2013-01-21 |
| Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids Elagolix, Placebo, Estradiol/Norethindrone acetate (E2/NETA) - Heavy Uterine Bleeding, Uterine Fibroids | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 271 | 2011-09-08 | 2021-07-13 |
| Mifepristone to Treat Uterine Fibroids Oral administration of mifepristone 2.5 mg daily for three months, Oral administration of mifepristone 5 mg daily for three months - Uterine Fibroids | Phase 2 / Phase 3 | Terminated | Mediterranea Medica S. L. | 220 | 2010-03-01 | 2014-09-05 |
| Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids Philips MR guided HIFU system - Uterine Fibroids, Uterine Leiomyomata | Phase 1 / Phase 2 | Completed | Philips Healthcare | 11 | 2009-01-01 | 2012-12-04 |
| An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext 25 mg Proellex - Uterine Fibroids | Phase 2 | Terminated | Repros Therapeutics Inc. | 4 | 2008-06-01 | 2014-08-25 |
| Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids Proellex 25 mg, Proellex 50 mg, Lupron Depot - Uterine Fibroids | Phase 2 | Terminated | Repros Therapeutics Inc. | 10 | 2008-05-01 | 2014-08-21 |
| Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids Mifepristone - Uterine Fibroids | Phase 2 / Phase 3 | Completed | Mediterranea Medica S. L. | 100 | 2008-05-01 | 2014-10-17 |
| Mifepristone for Treatment of Uterine Fibroids Mifepristone - Uterine Fibroids | Phase 2 / Phase 3 | Completed | Mediterranea Medica S. L. | 200 | 2007-01-01 | 2009-04-23 |
| Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 Proellex® - Uterine Fibroids | Phase 2 | Completed | Repros Therapeutics Inc. | 65 | 2006-09-07 | 2019-06-18 |
| A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids. Leuprorelin (GF), Leuprorelin (GC) - Uterine Fibroids | Phase 2 | Completed | Takeda | 80 | 2006-06-01 | 2010-06-22 |
| Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids 12.5 mg Proellex, 25 mg Proellex, Placebo - Uterine Fibroids | Phase 2 | Completed | Repros Therapeutics Inc. | 144 | 2006-03-01 | 2014-07-08 |
Showing 20 of 21. Sign in to see all of them.
Leiomyoma (21) · Menorrhagia (2) · Myofibroma (2) · Fibroma (1) · Uterine Neoplasms (1)
Neoplasms (21) · Neoplasms by Histologic Type (21) · Neoplasms, Connective and Soft Tissue (21) · Neoplasms, Muscle Tissue (21) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Neoplasms, Connective Tissue (3) · Urogenital Diseases (3) · Uterine Diseases (3) · Connective Tissue Diseases (2) · Hemorrhage (2) · Menstruation Disturbances (2) · Pathologic Processes (2)
telapristone acetate (10) · Estradiol (2) · Leuprolide (2) · Mifepristone (2) · Norethindrone Acetate (2) · elagolix (2) · estradiol, norethindrone drug combination (2) · Progesterone (1) · Sugars (1) · Uterine Artery Embolization (1) · asoprisnil (1) · relugolix (1)
Repros Therapeutics Inc. (10) · Mediterranea Medica S. L. (3) · Philips Healthcare (2) · Takeda (2) · AbbVie (1) · AbbVie (prior sponsor, Abbott) (1) · Abbott (1) · Karolinska Institutet (1)
United States (11) · Cuba (3) · Canada (1) · Japan (1) · Mexico (1) · South Korea (1) · Sweden (1)
Anna Chan (4) · Amanda Yunker, D.O. (1) · Andre VanAs, PhD, MD (1) · Andre van As, MD, PhD (1) · Aytekin Oto, MD (1) · Carbonell Josep Ll., MD (1) · Charlotte Owens, MD (1) · Elizabeth David, MD (1) · Helena Kopp Kallner, MD, PhD (1) · Hyo Keun Lim, MD (1) · John H Fischer II, MD (1) · Josep LL. Carbonell, MD (1)
PMID 17339234, PMID 22626269, PMID 23984082, PMID 25634727, PMID 27733082, PMID 30303923, PMID 34711224, PMID 35134317
2005 (1)